EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation

Entwicklung eines neuartigen multiepitopen mRNA-Impfstoffs gegen Hendra-Virus (HeV): integrativer Ansatz mit Immunoinformatik, Reverse Vaccinology und Molekulardynamiksimulation

Ahmad Abdullah Mahdeen, Imam Hossain iD, Md Habib Ullah Masum iD, Sajedul Islam, T M Fazla Rabbi

PLOS ONE · 23.10.2024 · 19 (10) · e0312239

DOI: 10.1371/journal.pone.0312239 ↗

Auf einen Blick

Eine In-silico-Studie entwarf einen multiepitopen mRNA-Impfstoff gegen HeV aus G-, F- und M-Proteinen. Die Modellierungen sagten breite Epitop-Abdeckung und stabile Bindung an TLR-2/TLR-4 voraus.

Fragestellung

Wie lässt sich ein multiepitoper mRNA-Impfstoff gegen HeV auf Basis von G-, F- und M-Proteinen computergestützt designen?

Methode

In-silico-Designstudie mit Immunoinformatik, Reverse Vaccinology und Molekulardynamiksimulation; Analyse von B- und T-Zell-Epitopen, Docking und Codon-Optimierung.

Ergebnisse

Die Impfstoffkonstruktion deckte 91,81 % der CTL- und 98,55 % der HTL-Epitope weltweit ab. GRAVY: -0,503; Ramachandran-Score: 88,5 %; Z-Score: -3,44; Docking mit TLR-4: -1139,4 KJ/mol, TLR-2: -1277,9 KJ/mol.

Einschränkungen

Es handelt sich um eine rechnerische Vorhersage; Wirksamkeit und Sicherheit wurden nicht experimentell belegt.

Schlussfolgerung der Autor:innen

Der potenzielle HeV-Impfstoff zeigte in den Analysen günstige Eigenschaften, benötigt aber weitere Studien zum Nachweis von Wirksamkeit und Sicherheit.

Kernaussagen

  • G-, F- und M-Epitope wurden zu einem mRNA-Konstrukt kombiniert.
  • 91,81 % CTL- und 98,55 % HTL-Epitop-Abdeckung weltweit.
  • Stabile Komplexe mit TLR-2 und TLR-4 wurden vorhergesagt.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 23.10.2024. Verfasst von Ahmad Abdullah Mahdeen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Hendra Virus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human and animal health is threatened by Hendra virus (HeV), which has few treatments. This in-silico vaccine design study focuses on HeV G (glycoprotein), F (fusion protein), and M (matrix protein). These proteins were computationally assessed for B and T-cell epitopes after considering HeV strain conservation, immunogenicity, and antigenicity. To improve vaccination immunogenicity, these epitopes were selectively ligated into a multiepitope construct. To improve vaccination longevity and immunological response, adjuvants and linkers were ligated. G, F, and M epitopes were used to create an mRNA HeV vaccine. Cytotoxic, helper, and linear B-lymphocytes’ epitopes are targeted by this vaccine. The population coverage analysis demonstrates that multi-epitope vaccination covers 91.81 percent of CTL and 98.55 percent of HTL epitopes worldwide. GRAVY evaluated the vaccine’s well-characterized physicochemical properties -0.503, indicating solubility and functional stability. Structure analysis showed well-stabilized 2° and 3° structures in the vaccine, with alpha helix, beta sheet, and coil structures (Ramachandran score of 88.5% and Z score of -3.44). There was a strong affinity as shown by docking tests with TLR-4 (central score of -1139.4 KJ/mol) and TLR-2 (center score of -1277.9 KJ/mol). The coupled V-apo, V-TLR2, and V-TLR4 complexes were tested for binding using molecular dynamics simulation where extremely stable complexes were found. The predicted mRNA structures provided significant stability. Codon optimization for Escherichia . coli synthesis allowed the vaccine to attain a GC content of 46.83% and a CAI score of 1.0, which supports its significant expression. Immunological simulations indicated vaccine-induced innate and adaptive immune reactions. Finally, this potential HeV vaccine needs more studies to prove its efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Dynamics SimulationHendra VirusHumansmRNA VaccinesVaccinologyViral VaccinesComputational BiologyEpitopes, B-LymphocyteEpitopes, T-LymphocyteHenipavirus InfectionsAnimalsVaccines, SyntheticImmunoinformatics

Substanzen

mRNA VaccinesViral VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • Faculty of Biotechnology and Genetic Engineering, Department of Genomics and Bioinformatics, Chattogram Veterinary and Animal Sciences University (CVASU), Chattogram, Bangladesh.

ORCID-Profile: Imam Hossain, Md Habib Ullah Masum

Zitieren

APA

Mahdeen, A. A., Hossain, I., Masum, M. H. U., Islam, S., & Rabbi, T. M. F. (2024). Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation. PLOS ONE, 19(10), e0312239. https://doi.org/10.1371/journal.pone.0312239

Vancouver

Mahdeen AA, Hossain I, Masum MHU, Islam S, Rabbi TMF. Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation. PLOS ONE. 2024;19(10):e0312239. doi:10.1371/journal.pone.0312239

BibTeX
@article{Mahdeen2024,
  author = {Mahdeen, Ahmad Abdullah and Hossain, Imam and Masum, Md Habib Ullah and Islam, Sajedul and Rabbi, T M Fazla},
  title = {Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {10},
  pages = {e0312239},
  doi = {10.1371/journal.pone.0312239}
}
Kostenlos starten →